Medicare Enrolled
Dr. Yelena Krupitskaya, M.D.
Hematology & Oncology · Pleasant Hill, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Krupitskaya from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Krupitskaya?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Krupitskaya
Dr. Yelena Krupitskaya is a hematology & oncology specialist in Pleasant Hill, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Krupitskaya performed 35,626 Medicare services across 1,510 unique beneficiaries.
Between the years covered by Open Payments, Dr. Krupitskaya received a total of $6,321 from 60 pharmaceutical and/or device companies across 282 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Krupitskaya is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ Top 18% volume in CA
$6,321 industry payments
Medicare Practice Summary
Medicare Utilization ↗35,626
Medicare services
Top 18% in CA for hematology & oncology
1,510
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,979 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
20,400 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 7,860 | $18 | $54 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
2,940 | $6 | $45 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
794 | $0 | $1 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
434 | $160 | $406 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
417 | $8 | $15 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
396 | $8 | $44 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
379 | $109 | $305 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
351 | $10 | $58 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
204 | $14 | $75 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
178 | $6 | $27 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
135 | $13 | $65 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
135 | $30 | $113 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
129 | $141 | $514 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
126 | $72 | $222 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
123 | $16 | $79 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
102 | $108 | $347 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
97 | $68 | $244 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
82 | $19 | $87 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
74 | $1 | $4 |
| Uric acid level test A blood test that measures the level of uric acid in your body. Uric acid is a waste product formed when the body breaks down purines. |
52 | $4 | $20 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
38 | $29 | $111 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
31 | $80 | $210 |
| Vitamin D level test A blood test to measure the amount of Vitamin D-3 in your body. |
27 | $29 | $136 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
25 | $156 | $461 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
21 | $44 | $145 |
| New patient office visit, complex (60-74 min) | 19 | $208 | $569 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
17 | $16 | $70 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
16 | $28 | $90 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
13 | $145 | $585 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
11 | $118 | $412 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
58.3% high complexity
33.8% medium
7.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,321
Total received (2018-2024)
Avg $903/year across 7 years
Top 39% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
282
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,077 (96.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$244 (3.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$978
2023
$2,147
2022
$816
2021
$821
2020
$333
2019
$775
2018
$452
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$146
Novartis Pharmaceuticals Corporation
$115
Merck Sharp & Dohme LLC
$101
Janssen Biotech, Inc.
$66
PFIZER INC.
$61
Ipsen Biopharmaceuticals, Inc
$60
Celgene Corporation
$58
E.R. Squibb & Sons, L.L.C.
$58
SpringWorks Therapeutics, Inc.
$51
Daiichi Sankyo Inc.
$39
Immunocore Limited
$39
GENZYME CORPORATION
$32
Lilly USA, LLC
$25
Tactile Systems Technology Inc
$25
SERVIER PHARMACEUTICALS LLC
$24
Agios Pharmaceuticals, Inc.
$22
Gilead Sciences, Inc.
$22
AstraZeneca Pharmaceuticals LP
$18
ARRAY BIOPHARMA INC
$17
Top 3 companies account for 37.0% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$551
Amgen Inc.
$425
Janssen Biotech, Inc.
$412
PFIZER INC.
$408
Daiichi Sankyo Inc.
$339
Novartis Pharmaceuticals Corporation
$285
Celgene Corporation
$277
Pharmacyclics LLC, An AbbVie Company
$272
Merck Sharp & Dohme LLC
$271
AstraZeneca Pharmaceuticals LP
$246
Kite Pharma, Inc.
$219
Lilly USA, LLC
$195
GENZYME CORPORATION
$180
Seagen Inc.
$177
ABBVIE INC.
$169
Clovis Oncology, Inc.
$118
Genentech USA, Inc.
$113
Array BioPharma Inc.
$102
Exelixis Inc.
$92
Gilead Sciences, Inc.
$82
Takeda Pharmaceuticals U.S.A., Inc.
$77
TerSera Therapeutics LLC
$70
Tactile Systems Technology Inc
$67
Ipsen Biopharmaceuticals, Inc
$60
TAIHO ONCOLOGY, INC.
$60
ARRAY BIOPHARMA INC
$55
Pharmacyclics LLC, an AbbVie Company
$53
SpringWorks Therapeutics, Inc.
$51
Astellas Pharma US Inc
$50
SOBI, INC
$48
Jazz Pharmaceuticals Inc.
$48
Merck Sharp & Dohme Corporation
$47
EMD Serono, Inc.
$43
Foundation Medicine, Inc.
$42
Immunocore Limited
$39
Myovant Sciences Inc.
$39
Taiho Oncology, Inc.
$36
PharmaEssentia USA Corporation
$33
PORTOLA PHARMACEUTICALS, INC.
$32
Regeneron Healthcare Solutions, Inc.
$31
TESARO, Inc.
$25
Otsuka America Pharmaceutical, Inc.
$25
ImmunoGen, Inc.
$24
Mirati Therapeutics, Inc.
$24
SERVIER PHARMACEUTICALS LLC
$24
Sobi, Inc
$23
Apellis Pharmaceuticals, Inc.
$23
Agios Pharmaceuticals, Inc.
$22
Genmab U.S., Inc.
$22
EISAI INC.
$21
Incyte Corporation
$20
Rigel Pharmaceuticals, Inc.
$20
Bayer HealthCare Pharmaceuticals Inc.
$20
Octapharma USA, Inc.
$20
Eisai Inc.
$19
Alnylam Pharmaceuticals Inc.
$18
Janssen Pharmaceuticals, Inc
$17
JAZZ PHARMACEUTICALS INC.
$16
Sunovion Pharmaceuticals Inc.
$14
TherapeuticsMD, Inc.
$13
Top 3 companies account for 22.0% of all-time payments
Associated products mentioned in payments ›
ALIMTA · ANDEXXA · APTIOM · Abraxane · Alecensa · Avastin · BAVENCIO · BESREMI · BOSULIF · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ENHERTU · EPKINLY · ERLEADA · EVENITY · Elahere · Enhertu · Epkinly · FASLODEX · Fabhalta · Flexitouch Plus · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · IMVEXXY · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MYLOTARG · NINLARO · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PYRUKYND · Padcev · Pomalyst · Prolia · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SPRYCEL · SUTENT · TAGRISSO · TASIGNA · TECENTRIQ · TEPMETKO · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · VENCLEXTA · VERZENIO · VPRIV · VYXEOS · Vanflyta · XALKORI · XARELTO · Xofigo · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
105
Per 100K population
9.0
County median income
$125,727
Nearest hospital
JOHN MUIR MEDICAL CENTER - CONCORD CAMPUS
3.5 mi
3.5 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Krupitskaya is a mixed practice specialist, with above-average Medicare volume (top 18% in CA), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Krupitskaya experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Krupitskaya performed 20,400 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Krupitskaya receive payments from pharmaceutical companies?
Yes. Dr. Krupitskaya received a total of $6,321 from 60 companies across 282 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Krupitskaya's costs compare to other hematology & oncology specialists in Pleasant Hill?
Dr. Krupitskaya's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Krupitskaya) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Pleasant Hill
Browse hematology & oncology specialists in Pleasant Hill ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology